|
|
EN
  • 业务咨询

    中国:

    Email: marketing@gdrzzg.com

    业务咨询专线:400-780-8018

    (仅限服务咨询,其他事宜请拨打川沙总部电话)

    川沙总部电话: +86 (21) 5859-1500

    海外:

    +1(626)986-9880(U.S. - West Coast)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

在线留言×
点击切换
Customer Center
客户中心

TAK-931是一种高效的CDC7抑制剂,通过抑制CDC7来抑制DNA复制,具有抗肿瘤功效,体内药效研究通过合乐HL8进行

2023-08-21
|
访问量:

Replication stress (RS) is a cancer hallmark; chemotherapeutic drugs targeting RS are widely used as treatments for various cancers. To develop next-generation RS-inducing anticancer drugs, cell division cycle 7 (CDC7) has attracted attention as a target. Researchers have developed an oral CDC7-selective inhibitor, TAK-931, as a candidate clinical anticancer drug.

TAK-931 demonstrated marked, dose-dependent antitumor activity, without severe body weight loss.

Antitumor efficacy studies for TAK-931 were carried out in two pancreatic PDX models, PHTX-249Pa and PHTXM-97Pa, at Medicilon. 

70.pngReference:

Kenichi Iwai, et al. Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor. Sci Adv. 2019 May 22;5(5):eaav3660. doi: 10.1126/sciadv.aav3660. 

相关新闻